Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKesson
Mallinckrodt
AstraZeneca
Merck

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Pegaspargase

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Pegaspargase: Patents, clinical trial progress, indications

Pegaspargase is an investigational drug.

There have been 109 clinical trials for Pegaspargase. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2011.

The most common disease conditions in clinical trials are Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and Leukemia, Lymphoid. The leading clinical trial sponsors are National Cancer Institute (NCI), Children's Oncology Group, and Sun Yat-sen University.

There are ninety-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Pegaspargase
TitleSponsorPhase
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyNational Cancer Institute (NCI)Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyChildren's Oncology GroupPhase 3
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell LymphomaRuijin HospitalPhase 2

See all Pegaspargase clinical trials

Clinical Trial Summary for Pegaspargase

Top disease conditions for Pegaspargase
Top clinical trial sponsors for Pegaspargase

See all Pegaspargase clinical trials

US Patents for Pegaspargase

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pegaspargase   See Pricing TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) YALE UNIVERSITY (New Haven, CT)   See Pricing
Pegaspargase   See Pricing Substituted 6-aminopurines for targeting HSP90 Duke University (Durham, NC)   See Pricing
Pegaspargase   See Pricing Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer YALE UNIVERSITY (New Haven, CT)   See Pricing
Pegaspargase   See Pricing Method of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   See Pricing
Pegaspargase   See Pricing Occidiofungin formations and uses thereof MISSISSIPPI STATE UNIVERSITY (Starkville, MS) THE TEXAS A&M UNIVERSITY SYSTEM (College Station, TX)   See Pricing
Pegaspargase   See Pricing Compounds for use in treating or preventing cancerous diseases BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pegaspargase

Drugname Country Document Number Estimated Expiration Related US Patent
Pegaspargase World Intellectual Property Organization (WIPO) 2013166110 2032-05-02   See Pricing
Pegaspargase European Patent Office 2879675 2032-08-06   See Pricing
Pegaspargase World Intellectual Property Organization (WIPO) 2014025395 2032-08-06   See Pricing
Pegaspargase China 105407920 2033-05-03   See Pricing
Pegaspargase European Patent Office 2991677 2033-05-03   See Pricing
Pegaspargase Hong Kong 1222564 2033-05-03   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Johnson and Johnson
McKesson
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.